Biolex Therapeutics will produce two additional commercial lines for monoclonal antibodies under an expanded contract with therapeutics firm Medarex.

Monoclonal antibodies are produced from clones of an immune cell.

Biolex created a commercial line for one monoclonal antibody under an agreement reached with Medarex last year.

Biolex utlizes a production system known as LEX that utilizes the acquatic plant lemna.